Innoviva (INVA) Q2 Sales Jump 64%
(NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share (GAAP) of $0.77 on $100.3 million in revenue. The period featured a jump in specialty therapeutics sales and Favorable investment gains offset a year-over-year drop in operating profit from higher research and development expenditures. Overall, the quarter highlighted progress on product launches and regulatory advances, even as near-term margin pressures surfaced.
Source: Analyst estimates for the quarter provided by FactSet.
Innoviva earns most of its money from pharmaceutical royalties, particularly through a partnership with GlaxoSmithKline for respiratory treatments. Over recent years, Innoviva has moved toward directly selling its own specialty therapies, especially for infectious diseases and critical care, such as GIAPREZA, XACDURO, and XERAVA.
Source Fool.com
Innoviva Inc. Aktie
Leichtes Kaufinteresse bei Innoviva Inc., mit mehr Buy- als Sell-Einschätzungen.
Die Community erwartet für Innoviva Inc. ein Kursziel von 24 €, was eine Steigerung von über 20% gegenüber 17.2 € bedeuten würde.
